Trials / Completed
CompletedNCT03807440
DIA_CENTRAL:T2D Treatment Pattern in Central Europe
CORDIALLY® - CEE: Characteristics of Patients With Type 2 Diabetes Treated With Modern Antidiabetic Drugs. A Real World Data Collection of Patient Baseline Characteristics, Treatment Patterns and Comorbidities in Central Eastern European (CEE) Countries
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,083 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-interventional study using existing data including medical chart review.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin | Empagliflozin |
| DRUG | Sodium Glucose Transporter 2 inhibitor | Sodium Glucose Transporter 2 inhibitor |
| DRUG | Dipeptidyl-peptidase 4 inhibitor | Dipeptidyl-peptidase 4 inhibitor |
| DRUG | Glucagon-like peptide 1 agonist | Glucagon-like peptide 1 agonist |
Timeline
- Start date
- 2019-08-26
- Primary completion
- 2021-08-31
- Completion
- 2021-08-31
- First posted
- 2019-01-17
- Last updated
- 2023-12-01
- Results posted
- 2023-12-01
Locations
177 sites across 5 countries: Bulgaria, Czechia, Hungary, Poland, Russia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03807440. Inclusion in this directory is not an endorsement.